A combined genome-wide association and linkage study was used to identify loci causing variation in cystic fibrosis lung disease severity. We identified a significant association (P = 3.34 × 10 −8 ) near EHF and APIP (chr11p13) in p.Phe508del homozygotes (n = 1,978). The association replicated in p.Phe508del homozygotes (P = 0.006) from a separate family based study (n = 557), with P = 1.49 × 10 −9 for the three-study joint meta-analysis. Linkage analysis of 486 sibling pairs from the family based study identified a significant quantitative trait locus on chromosome 20q13.2 (log 10 odds = 5.03). Our findings provide insight into the causes of variation in lung disease severity in cystic fibrosis and suggest new therapeutic targets for this life-limiting disorder.
Lung disease is the major source of morbidity and mortality in cystic fibrosis, a recessive disorder caused by mutations in CFTR, the cystic fibrosis transmembrane conductance regulator gene. Allelic variation in CFTR does not explain the wide variation in severity of lung disease 1 , however, studies of twins and siblings show substantial heritability underlying the differences in lung function measures in individuals with cystic fibrosis (h 2 > 0.5) (ref. 2) . Candidate gene studies have produced conflicting results, with only a few large-scale replications accounting for a small proportion of heritable variation in cystic fibrosis lung function 3, 4 . Identification of other genetic modifiers could identify potential mechanisms for variation in lung function in cystic fibrosis, as well as for common diseases such as chronic obstructive pulmonary disease, and suggest new targets for intervention.
Whole-genome methods provide an attractive approach to identify modifier loci of Mendelian disorders. However, cystic fibrosis presents numerous challenges, such as (i) collecting multiple years of lung function measures to accurately classify lung disease severity; (ii) selecting the appropriate study design to identify common and rare variants; (iii) accruing sufficient sample sizes; and (iv) accounting for potential interaction between CFTR and modifier loci. To overcome these challenges, we formed the North American Cystic Fibrosis Gene Modifier Consortium to identify modifiers of lung disease severity and other phenotypes. For lung disease in cystic fibrosis, the forced expiratory volume in 1 s (FEV 1 ) is the most clinically useful measure of lung disease severity and is a well-established predictor of survival 5, 6 . However, comparison of FEV 1 measures across a broad age range of individuals with cystic fibrosis is confounded by decline with age and mortality attrition. To account for these confounders, the Consortium developed a quantitative lung disease phenotype based on multiple measures of FEV 1 over 3 years 7 that displays robust genetic influence (h 2 = 0.51) (ref. 8 ).
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2
A r t i c l e s
The Consortium is composed of three samples of individuals with cystic fibrosis recruited using different study designs. The Genetic Modifier Study (GMS) consists of unrelated individuals homozygous for the common cystic fibrosis allele p.Phe508del recruited from extremes of lung function 9 . The Canadian Consortium for Genetic Studies (CGS) enrolled unrelated individuals with pancreatic insufficiency from a population-based sample 10 . The cystic fibrosis Twin and Sibling Study (TSS) recruited families in which two or more surviving children have cystic fibrosis 2 . The GMS and CGS were designed for association analysis, whereas the TSS was designed for both linkage and association, providing an opportunity to detect rarer variants or poorly tagged loci.
As many current genome-wide association studies (GWAS) use sample sizes that are several fold larger than those available for the population of individuals with cystic fibrosis, we sought to maximize power by (i) testing the association using combined data from GMS and CGS followed by replication using the association evidence from TSS and (ii) testing linkage using the TSS data followed by SNP association testing in linked regions in the unrelated individuals from GMS and CGS. We restricted our analysis to individuals with two severe loss-of-function CFTR alleles and a subset that had identical CFTR genotypes (homozygosity for p.Phe508del).
RESULTS

Association analysis of lung disease severity in cystic fibrosis
A total of 3,467 individuals with cystic fibrosis are represented in three study designs ( Table 1 and Supplementary Note). Individuals in the GMS and 60% of those in the CGS and TSS are p.Phe508del homozygotes (p.Phe508del/p.Phe508del), whereas the remainder have other severe exocrine pancreatic CFTR genotypes 2,9,10 . The three samples showed consistent distributions of the lung disease phenotype, with the mid-range underrepresented in GMS because of the 'extremes of phenotype' design ( Fig. 1) . We contemporaneously genotyped affected individuals using the Illumina 610-Quad array in a single facility with stringent quality control measures (Online Methods). Association scans for GMS and CGS used an additive model adjusted for sex and principal components as described 11 . We combined results using a directional meta-analysis approach for (i) GMS and CGS, n = 2,494, and (ii) GMS and CGS p.Phe508del/p.Phe508del, n = 1,978 (the power analysis is shown in Supplementary Fig. 1 ).
The combined GMS and CGS analysis identified seven regions with suggestive association (P ≤ 1/570,725 = 1.75 × 10 −6 ) ( Fig. 2 and Table 2 ). Restricting the analysis to individuals with p.Phe508del/ p.Phe508del, the EHF-APIP region on 11p13 reached genome-wide significance at rs12793173 (P = 3.34 × 10 −8 , explaining 1.0% of the phenotype variation in GMS and 2.2% of the variation in CGS individuals with p.Phe508del/p.Phe508del). We verified this significance by permutation analysis and by developing an alternative conditional likelihood approach that acknowledged the GMS extremes of phenotype (Online Methods and Supplementary Fig. 2 ). With the inclusion of cystic fibrosis-relevant covariates (sex, body mass index (BMI) and previously associated genes), the association for rs12793173 was even stronger (P = 9.42 × 10 −9 for GMS and CGS p.Phe508del/p.Phe508del;
Supplementary Table 1) . Two purported modifiers of cystic fibrosis lung disease, TGFB1 and IFRD1, did not achieve genome-wide significance. TGFB1 did, however, achieve P values in the range of P = 10 −3 to P = 10 −4 in the GMS sample, depending on additional covariates (Supplementary Table 1) .
We evaluated the SNPs in the significant region and the six suggestive regions in GMS and CGS for association in TSS using MERLIN 12 while accounting for family structure. To be consistent with the GMS and CGS allelic effect, each replication test was one sided, and we chose the TSS sample (either all or individuals with p.Phe508del/ p.Phe508del) for each suggestive SNP to be consistent with the GMS and CGS sample that provided maximum significance. We included covariates for sex and four principal components 11 for TSS. The SNP attaining genome-wide significance in GMS and CGS (rs12793173, p.Phe508del/p.Phe508del) showed significant association in the TSS p.Phe508del/p.Phe508del sample (P = 0.006; Bonferroni corrected P = 0.041 for the seven replication tests; Table 2 ). Two of the suggestive SNPs provided modest evidence in TSS: rs9268905 near HLA-DRA (P = 0.032) and rs1403543 near AGTR2 (P = 0.053), and neither was significant after correcting for the seven replication tests.
We next performed a joint analysis, which has been shown to be more powerful than testing followed by replication 13 , using a weighted meta-analysis procedure (Online Methods). Using all affected subjects, rs12793173 attained genome-wide significance (P = 1.12 × 10 −8 ). For this subject set, rs568529, a SNP in high linkage disequilibrium (LD) (r 2 > 0.9) with rs12793173, achieved slightly greater significance (P = 9.75 × 10 −9 ). As in the earlier analysis, restricting the analysis to individuals with p.Phe508del/ p.Phe508del increased the significance of EHF-APIP (P = 1.49 × 10 −9 for rs12793173 ( Table 2 ) and P = 8.28 × 10 −10 for rs568529). 
A r t i c l e s
In the HLA class II region, a SNP (rs2395185, ~1 kb from the suggestive SNP rs9268905 identified from GMS and CGS) approached genome-wide significance using all affected subjects (P = 9.02 × 10 −8 ; Supplementary  Fig. 3 ). SNPs in AGTR2 remained suggestive for all affected subjects (rs5952206, P = 1.25 × 10 −7 ) and for individuals with p.Phe508del/p.Phe508del (rs7060450, P = 3.67 × 10 −7 ). Figure 3 shows the GMS and CGS results for an 800-kb interval including EHF-APIP. The minimum P value is in an intergenic region 3′ to both EHF and APIP. A second peak at rs286873 (P = 5.62 × 10 −7 ) near EHF had low linkage disequilibrium (r 2 < 0.2) with the primary SNP (Fig. 3) . After conditioning on the primary finding, rs286873 had regional statistical significance (rs12793173; corrected P = 0.0029), suggesting additional regional genetic variants (Supplementary Fig. 4) . We repeated the testing after MACH imputation 14 . The imputed SNPs in the region identified the same EHF-APIP interval with a minimum P = 1.45 × 10 −8 at rs535719, which is at a position 19 kb closer to APIP than rs12793173. None of the imputed SNPs produced substantially improved association evidence (Supplementary Fig. 5 ). Neither the total copy number nor the allele-specific copy number (Online Methods) models met genome-wide significance (the illustrative Manhattan plot is shown in Supplementary Fig. 6 ). Finally, after sequencing the exonic regions of EHF and APIP in 48 individuals with mild pulmonary disease and 48 individuals with severe pulmonary disease from the GMS, we found no additional genetic variation that offered insight into putative modifying roles (data not shown).
Linkage of lung disease severity in cystic fibrosis analysis
Linkage analysis revealed a genome-wide significant multipoint log 10 odds (LOD) score of 5.03 at rs4811626 at 53.81 Mb (~85 cM) on chromosome 20q13.2 (nominal P = 7.9 × 10 −7 ; genome-wide 15 P = 2.3 × 10 −3 ; Fig. 4) . Another, but more modest, linkage signal was on chromosome 1p22.21, with a multipoint LOD score of 2.48 for rs941031at 91.07 Mb (119 cM). Inclusion of BMI z score (BMI-Z), an important covariate of cystic fibrosis lung function (Supplementary Table 1) , increased the LOD score for the linkage peak on 20q13.2 to 5.72 (genome-wide P = 5.05 × 10 −4 at rs4811645, which is 0.07 cM (0.13 Mb) from rs4811626; Supplementary Fig. 7) ; however, this estimate is highly likely to be biased upward because of winner's curse 16 .
We analyzed a 1.31-Mb region on 20q13.2, demarcated by 1 LOD unit below the maximum (when we used BMI-Z as a covariate), for association in the combined GMS and CGS samples. A 16-kb cluster of SNPs in high LD (rs6092179, rs6024437, rs8125625, rs6024454 and rs6024460; r 2 > 0.8), located ~200 kb from CBLN4, generated the lowest P values in the combined GMS and CGS p.Phe508del/ p.Phe508del samples (Fig. 5) . The SNP with the lowest P value (rs6024460; P = 1.34 × 10 −4 ) reached regional significance (corrected P = 0.041). Association in the TSS identified a SNP (rs6069437) with marginal association (uncorrected P = 0.014) that showed weak LD with the GMS and CGS cluster of SNPs. Imputation did not identify any SNPs with a lower P value for association than rs6024460 (Supplementary Fig. 8 ).
An FDR approach to combine association and linkage
To evaluate association and linkage in a single framework, we used linkage information to reprioritize genome-wide association using extensions of the false discovery rate (FDR) 17 , that is, the stratified FDR (SFDR) 18 and weighted FDR (WFDR) 19 . We (i) obtained linkageweighted q values representing the combined evidence at each SNP and (ii) re-ranked GWAS results by linkage-weighted q values (Online Methods). Results are presented from the WFDR; we confirmed results using the SFDR (data not shown). We declared SNPs with q values less than 0.05 to be genome-wide significant ( Table 3) . SNPs in the EHF-APIP region on chromosome 11 were highly significant (low q values) because of the strong association ( Table 3) . After accounting for linkage, the q values for SNPs under the linkage peak on chromosome 20 were considerably decreased. The results presented in Table 3 show that the linked SNPs on chromosome 20 are now top ranked genome wide, whereas they were ranked one hundred fifty-fourth or lower before incorporating the linkage information. The top-ranked SNP by the WFDR analysis was rs6092179 at 53.81 Mb on chromosome 20 (WFDR q value = 0.015; Table 3 ). rs6092179 is within an LD block containing four other SNPs (rs6024437, rs8125625, rs6024454 and rs6024460), all having association with cystic The secondary peak at rs286873 has relatively low r 2 with the primary peak. 
A r t i c l e s
fibrosis lung function and a q value < 0.05. A rank-based q value Manhattan plot shows that chromosome 11 and chromosome 20 both attained genome-wide significance (Supplementary Fig. 9 ).
DISCUSSION
We identified two new loci containing genetic variants contributing to variation in lung function in individuals with cystic fibrosis. The success of this project reflected (i) coordinated analysis of three independent samples of the cystic fibrosis population (representing ~15% of all affected individuals in North America) where each study subject was characterized by the same quantitative measure of lung function; (ii) simultaneous genotyping of samples using a single platform that allowed for data cleaning using relatedness assessments and removal of poor quality genotypes based on parent-to-child transmission predictions; and (iii) analyzing for loci using both association and linkage, which can detect loci even in the presence of substantial allelic heterogeneity. Moreover, we garnered increased power from an extremes-of-phenotype sample, and a population-based sample allowed for the development of a phenotype with external validity.
The association at chromosome 11p13 is in an intergenic region 3′ to APIP and EHF with regulatory features including (i) significant conservation across species, (ii) open chromatin (DNAase hypersensitivity and FAIRE-Seq) and (iii) DNAase hypersensitive patterns suggesting cell-type specificity (see URLs). The University of California at Los Angeles (UCLA) Gene Expression Tool (UGET; see URLs) 20, 21 indicates correlation of expression of nearby genes, including strong correlation of EHF to ELF5, both of which are epithelial-specific transcription factors; APIP to PDHX, which have the same promoter region; and EHF to APIP. APIP (encoding the Apaf-1-interacting protein) is known to inhibit apoptosis by binding to APAF-1, an important activator of caspase-9 (refs. 22,23) , and by APAF-1-independent activation of AKT and MAPK3 (ERK1) and MAPK1 (ERK2) (ref. 24) . EHF is a member of epithelial-specific Ets transcription factors that share a conserved Ets domain [25] [26] [27] . EHF can be induced in bronchial epithelial cells, smooth muscle cells and fibroblasts 28, 29 , leading to transcriptional repression of a subset of genes responsive to ETS and AP-1 that are activated by MAPkinase pathways 26, 28 , and in the airway, it may serve as an important regulator of differentiation under conditions of stress and inflammation 26, 27 . Both genes show evidence of robust expression in lung and trachea, with APIP showing ubiquitous expression across tissues and EHF showing the highest expression in trachea (see URLs) 30 . Notably, cis expression QTL (eQTL) signatures for APIP are reported for lymphocytes and monocytes (see URLs). Comparing the eQTLs to the direction of phenotypegenotype association suggests that increased expression of APIP may be associated with decreased lung function, implying that inhibition of apoptosis worsens cystic fibrosis lung disease. This hypothesis is consistent with the emerging concepts that delayed neutrophil clearance caused by reduced apoptosis in neutrophils in the airways of individuals with cystic fibrosis could lead to a hyper-inflammatory state and more severe lung disease 31, 32 and that inhibition of apoptosis contributes to goblet cell metaplasia, a central feature in cystic fibrosis airway pathophysiology 33 .
All five genes within the one LOD support interval in the chromosome 20 linkage region (Fig. 5) are expressed in either fetal or adult lung or in bronchial epithelial cells (see URLs). The 16-kb cluster of SNPs associated with lung function in the GMS and CGS samples is A r t i c l e s located ~200 kb to 500 kb centromeric to the five genes. None of the SNPs lies within a segment of open chromatin identified in the 16-kb region in normal human bronchial epithelia cells (see URLs). Neither eQTL in lymphocytes, miRNA (see URLs) nor DNaseI hypersensitive sites in small airway epithelial cells map to the 16-kb region. However, this does not exclude the possibility that the associated region regulates expression of any of the five genes or more distant genes. Among the five genes, MC3R has been implicated in weight maintenance and regulation of energy balance in animals and humans [34] [35] [36] . Variation in resting energy expenditure has been correlated with lung function measurements, lung tissue damage and lung disease exacerbation in individuals with cystic fibrosis 37, 38 . MC3R has also been implicated as a modulator of neutrophil accumulation in a mouse model of lung inflammation 39 , a key feature of cystic fibrosis lung disease, as noted above. Other genes of interest within the linkage peak encode Crkassociated substrate scaffolding (CASS) 4 (encoded by CASS4, also known as HEPL), a relative of proteins implicated in cell attachment, migration establishing polarity, invasion and phagocytosis of bacterial pathogens 40 , and Aurora kinase A (encoded by AURKA), which has been shown to interact with Hef1, also known as NEDD9, a member of the CASS family that mediates cytokinesis in late mitosis and facilitates disassembly of primary cilia 41 .
Twin studies in adults show that FEV 1 is under strong genetic influence in the general population 42, 43 , and at least three loci (GSTCD, TNS1 and HTR4) have been reproducibly associated with this measure [44] [45] [46] . Multiple replicated loci have also been associated with variation in the ratio of FEV 1 to forced vital capacity (FVC) 45, 46 , and at least two of these loci (HHIP and FAM13) showed reproducible association with COPD 44, 47, 48 . Although the lung phenotype used here was based on FEV 1 , none of the above loci coincides with the regions identified in this study, and neither of the loci identified here occur within the top 2,000 associations for FEV 1 or FEV 1 /FVC 45, 46 .
Common variation in the EHF-APIP region is estimated to alter the lung function measure in the GMS and CGS individuals with p.Phe508del/p.Phe508del by ~0.2 units of the quantitative lung disease phenotype per allele ( Table 2) . Translated into more familiar clinical terms, the 0.2 unit difference is approximately equivalent to a mean difference in predicted FEV 1 percent of 5.1 ± 1.9, corresponding to a mean difference in FEV 1 of 254 ± 86 ml in affected subjects over 18 years of age (Online Methods). The QTL on chromosome 20 may account for a sizeable fraction of lung function variation in cystic fibrosis. Using simulations previously described 16 , we estimate that this locus accounts for a maximum of 46% and a minimum of 4% of the variance in the cystic fibrosis-affected siblings (Online Methods).
In summary, our association and linkage approach provided complementary findings, with the identification of two significant loci harboring genes of biologic relevance for cystic fibrosis. Of particular note for modifier searches in other monogenic diseases is the potential importance of minimizing variation in the causative gene. When we confined association analysis to individuals with identical CFTR genotypes (that is, p.Phe508del/p.Phe508del), one of the seven suggestive loci achieved genome-wide significance despite the reduction in sample size because of the exclusion of 38% of subjects in the CGS sample with other CFTR genotypes. The remaining suggestive loci contain biologically intriguing candidate modifiers that will be evaluated in future studies. Finally, the identification of genetic loci that modify lung function in cystic fibrosis should provide new insight leading to the development of new therapies for this devastating condition. 
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. nominal result. Using the joint analysis based on GMS, CGS p.Phe508del/ p.Phe508del and TSS p.Phe508del/p.Phe508del subjects, the observed minimum P = 8.28 × 10 −8 resulted in ~28.0% reduction of the effect size. Using the rough parallel to explained variation in the trait, the estimated explained variation for 11p13 remained 1-2%. For a linkage study of comparable size (n = 500 sibling pairs) with a phenotype heritability of 0.5, the bias attributed to the winner's curse varies from approximately 0.46 down to 0 as the true (unmeasured) heritability attributable to the QTL increases 16 . Although it is not possible to quantify the magnitude of this bias in this single study, these calculations provide an upper bound on the bias of 0.38-0.46 and a lower bound of 0.04-0.12.
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Estimation of changes in the cystic fibrosis lung phenotype upon predicted FEV 1 percent and airway flow. Using 973 individuals from TSS, a hypothetical quantity of 0.2 was added to each individual's lung phenotype to correspond to the effect size observed for the significant association of SNPs near EHF-APIP. The average raw FEV 1 (in liters) was then back extrapolated 8 , and FEV 1 percent predicted values were generated using the predictive equations 59, 60 . Height and age adjustments used to calculate the original quantitative lung phenotype were preserved. The average increase (mean ± s.d.) in FEV 1 percent predicted corresponding to a 0.2-unit increase of our lung phenotype was 5.09% ± 1.90% (n = 841, range 0.00-14.53%). The corresponding average increase in raw FEV 1 was 253.5 ± 85.9 ml in adult subjects (defined as >18 years old) (n = 244, range: 0.0-630.0 ml).
